New Nanobody Discovery Service

Discovery of Novel Binders Using a Differentiated Synthetic Nanobody Library

Genexine has established a large-scale synthetic nanobody library based on nanobody germline sequences with high similarity to human antibody sequences.
Using this proprietary library, Genexine identifies nanobodies with high binding affinity and specificity to customer-defined antigens (targets) and provides optimized candidates through affinity maturation.

Advantages of Nanobodies

Small Size and Rapid Clearance from the Body

When applied to RPT (Radiopharmaceutical Therapy) development, renal toxicity issues can be overcome.

Excellent Tissue Penetration

Their small size enables efficient penetration into tissues and plasma.

Excellent Safety

Stable against heat, pH, and enzymes.

High Versatility

Easily applicable to various engineered fusion proteins and platforms.

Features of Genexine Nanobody Library

Human-like Single Framework

A single framework-based synthetic library utilizing a nanobody germline sequence similar to human antibody sequences to minimize potential immunogenicity.

Large Library Diversity

A large-scale nanobody library comprising approximately 1 × 10¹¹ variants.

High Functional Diversity

Tri-nucleotide-based library construction minimizes the occurrence of stop codons and frameshift mutations while maximizing the functional diversity of CDR-H3 amino acid sequences.

NGS-Validated Library

Confirm the diversity of amino acid sequences comprising CDR-H3 through NGS analysis.

High-Affinity Binder Discovery

Nanobodies with a KD of up to approximately 1 nM can be identified.

Affinity Maturation

Additional affinity maturation can be performed depending on the customer’s development objectives.

Nanobody Discovery Workflow

Services Provided

1. 1Discovery of novel nanobodies that bind to specific antigens
2. 2Nanobody screening and binder selection
3. 3Nanobody sequence analysis
4. 4Binding affinity assessment
5. 5Production and purification of candidate nanobodies
6. 6Affinity maturation
7. 7Joint development of novel pipelines with customers

Expansion into Various Drug Development Platforms

The discovered nanobodies can be utilized not only in antibody-based therapeutics but also as targeting binders for a wide range of next-generation drug development platforms.
In particular, Genexine is actively seeking opportunities for collaborative research and co-development of novel therapeutics, leveraging the experience and expertise in nanobody discovery and application accumulated through its in-house bioPROTAC research and development.